Although there is a robust body of evidence reporting the beneficial effect of the neurotrophin against retinal degeneration, NGF-based therapies are at the very early stages of market approval and clinical applicability due to several drawbacks that still require a solution, such as poor solubility, low delivery efficiency, short half-life and off-target effect [17]. This evidence concerns the gene NGF and retinal degeneration.